Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
DTCFF Stock Chart & Stats
$0.58
$0.06(15.36%)
At close: 4:00 PM EST
$0.58
$0.06(15.36%)
Day’s Range― - ―
52-Week Range$0.31 - $1.00
Previous CloseN/A
Volume8.00K
Average Volume (3M)599.00
Market Cap
$24.03M
Enterprise Value$33.81M
Total Cash (Recent Filing)$947.35K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding57,369,970
10 Day Avg. Volume40
30 Day Avg. Volume599
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-756.06
Enterprise Value/Ebitda-8.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Accum™ Intracellular Delivery PlatformAccum™ is a platform technology that improves intracellular delivery and immune activation. As a reusable delivery backbone across ADCs, vaccines and biologics, it provides a structural competitive advantage: one core asset can generate multiple programs, improving optionality and long-term upside if clinical translation succeeds.
Strategic Focus On Oncology And Infectious Disease MarketsTargeting oncology and infectious disease aligns the company with large, durable addressable markets and persistent R&D funding flows. These therapeutic areas favor platform technologies and partnerships, increasing chances of strategic collaborations and multiple commercialization pathways over a multi‑year horizon.
Material Reduction In Annual Net Loss And Improving Free Cash Flow TrendA substantial year-over-year reduction in net loss and an improving free cash flow trend indicate better cost control or program prioritization. If sustained, this enhances runway and reduces dilution risk, providing durable improvement in the firm's ability to finance development before commercialization.
Bears Say
Zero Revenue; No CommercializationThe company has no product revenue, meaning it remains pre-commercial and dependent on financing to fund operations. This elevates execution risk: successful clinical outcomes and partner deals are required to reach sustainable cash generation, a structural hurdle over the next several quarters.
Negative Shareholders' Equity And Elevated Balance-sheet RiskNegative equity constrains financial flexibility and can limit borrowing capacity, signaling prior dilution and accumulated losses. This structural weakness increases the likelihood of further equity raises, raising long-term financing costs and governance pressures that can impair program continuity.
Persistent Negative Operating Cash Flow And Ongoing Cash BurnSustained negative operating cash flow (~-4.9M TTM) demonstrates ongoing cash burn and dependence on external funding. Over a multi‑month horizon this constrains R&D cadence, forces capital raises, and can delay development milestones if financing terms or timing are unfavorable.
Defence Therapeutics News
DTCFF FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.31 and its highest was $1.00 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $24.03M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 22, 2026 which is in 56 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 20, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.02.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 57,369,970 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―